Treating Muscle Dysfunction Using Selective ERRg Compounds

SLU ID 17-026 | ERR Ligands For The Treatment Of Muscle Dysfunction

Background

Inverse agonists of the nuclear receptor estrogen related-receptor gamma (ERRg) have no known therapeutic benefits at present though there is the potential for them to be useful in treating certain cancers.

Overview

Researchers at Saint Louis University have developed novel and selective compounds that modulate the nuclear receptor estrogen related-receptor gamma. These modulators can be compounds that act as an agonist a the receptor or as an inverse agonist.

Benefits

The potential benefits of this technology include:

• Increasing the therapeutic benefit of inverse agonists of ERRg

• Increasing the selectivity of therapeutic compounds

• Minimizing difficulties of developing ERRg-based oral drugs

Applications

The potential applications of this technology include:

• Treating metabolic diseases (e.g., diabetes, obesity, muscle wasting, NASH)

• Treating muscular dystrophy

• Treating Duschene's muscular dystrophy

• Nutritional supplements

Opportunity

Saint Louis University is seeking partners to further develop and commercialize this technology.